menu search

Pharmazz inc. and sun pharma enter into licensing agreement for introducing tyvalzi™ (sovateltide) in india

Sovateltide is a first of its kind drug to treat acute cerebral ischemic stroke that can be administere...

September 14, 2023, 4:30 am

Selnoflast by f. hoffmann-la roche for coronary artery disease (cad) (ischemic heart disease): likelihood of approval

Selnoflast is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Coronary Artery Disease (CAD) (...

August 28, 2023, 3:44 am

Therma bright hails successful good laboratory practice study for breakthrough preva mechanical thrombectomy device

Therma Bright Inc (TSX-V:THRM, OTC:TBRIF) along with its partner Inretio Inc has highlighted the successful completion of a Good Laboratory Practice ...

June 8, 2023, 8:13 am

Diamedica therapeutics to report first quarter 2023 financial results and provide a business update may 16, 2023

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing r...

May 8, 2023, 8:50 am

Life biosciences presents groundbreaking data at arvo demonstrating restoration of visual function in nonhuman primates

Data in a nonhuman primate model of Non-arteritic Anterior ischemic Optic Neuropathy (NAION) demonstrat...

April 23, 2023, 5:30 pm

Diamedica therapeutics to report fourth quarter 2023 financial results and provide a business update march 29, 2023

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing r...

March 20, 2023, 4:17 pm

Therma bright says partner inretio moves to new manufacturing facility

Therma Bright Inc (TSX-V:THRM, OTC:TBRIF) said its partner Inretio Inc, a leading Israeli medical device startup and developer of the PREVA novel clot...

March 8, 2023, 8:41 am

Amarin announces new reduce-it® data at acc.23/wcc showing benefit of vascepa®/vazkepa® (icosapent ethyl) in high-risk patients with a recent acute coronary syndrome event

–Post-Hoc Analysis Shows IPE Significantly Reduced Risk of First, Total ischemic Events by 37% and 36...

March 5, 2023, 3:21 pm

Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve

Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...

March 4, 2023, 3:30 pm

Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve

Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...

March 4, 2023, 3:30 pm

Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve

Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...

March 4, 2023, 3:30 pm

Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve

Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...

March 4, 2023, 3:30 pm

Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve

Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...

March 4, 2023, 3:30 pm

Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve

Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...

March 4, 2023, 3:30 pm

Therma bright highlights positive study results for partner inretio's novel clot removal device for stroke treatment

Therma Bright Inc (TSX-V:THRM, OTC:TBRIF) said its partner Inretio Inc, a leading Israeli medical device startup developing a novel clot removal devic...

February 23, 2023, 8:46 am

Therma bright to invest up to us$2.5m in developer of a groundbreaking ischemic stroke treatment

Therma Bright Inc (TSX-V:THRM, OTC:TBRIF) said it has signed a share purchase agreement to buy up to a 25% stake in Inretio Ltd, an Israel-based com...

January 19, 2023, 9:11 am

Chf, left atrial enlargement predictive of af in patients with ischemic stroke

Researchers sought to determine the association between commonly evaluated risk factors and poststroke detection of new AF in the STROKE AF cohort mon...

January 3, 2023, 4:29 pm

Bristol myers (bmy) announces milvexian phase ii study results

Bristol Myers (BMY) announces AXIOMATIC-SSP study results of milvexian, an investigational oral factor XIa inhibitor, for preventing new symptomatic <...

August 29, 2022, 1:32 pm

Fda institutes clinical hold on diamedica's late-stage stroke trial - read why

The FDA placed a clinical hold on DiaMedica Therapeutics Inc's (NASDAQ: DMAC) Phase 2/3 ReMEDy2 trial evaluating DM199 to treat acute ...

July 7, 2022, 7:51 am

Athersys (athx) down as ischemic stroke study fails to meet goal

While a mid-stage/late-stage study evaluating Athersys' (ATHX) stem cell treatment for ischemic stroke ...

May 23, 2022, 4:34 pm


Search within

Pages Search Results: